Arrhythmia Research Technology, Inc. (ART) was founded in 1981 specifically to capitalize on the marketing of certain patents or licenses concerning the application of signal-averaged electrocardiography (SAECG) for the detection of cardiac late potentials.
Late potentials have been shown to be an indicator of risk for ventricular tachycardia (VT) which can degenerate into ventricular fibrillation and result in the sudden cardiac death syndrome, especially in post myocardial infarction patients. Sudden cardiac death afflicts over 400,000 individuals in the United States alone each year.
Today, ART’s SAECG products are used by major research institutions, hospitals and clinics throughout the world. In fact, the majority of all scientific and medical literature written about SAECG used the ART 1200EPX™ and PREDICTOR® product lines of signal-averaging systems! These systems and product lines have defined the industry and clinical standards for high resolution electrocardiography.
ART is dedicated to delivering state-of-the-art solutions for comprehensive cardiac care. Every ART product is a tangible result of our commitment to aid physicians and medical professionals in diagnosing and treating patients with heart disease. We provide a range of high quality, innovative tools based on the very best technology available.
ART’s Signal Averaging and Hemodynamics technology enable physicians to make significant strides in detecting and treating electrical and physical malfunctions of the heart. ART has extended the commitment to quality through MICRON Products, its subsidiary, which manufactures ECG silver/silver chloride-plated electrode sensor components. We continue to base our success on developing superior technology that helps physicians provide exceptional and cost-effective cardiac care.
ART is a publicly traded company under the “HRT” symbol in the NYSE:MKT . For more information and an annual report, please call ART Investor Relations at 1-(978)-602-1436.